Question 1

What is Revvity's P/E ratio?

Accepted Answer

Revvity (RVTY) P/E ratio is 51.3× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Revvity?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Revvity specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Revvity's P/E ratio high or low?

Accepted Answer

Revvity's P/E ratio of 51.3× is above its own 5-year average of 34.4× and above the sector median of 24.2×. That places the current reading at the 87th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Revvity's historical P/E ratio range?

Accepted Answer

In the available daily series, Revvity (RVTY) P/E ratio has ranged from a low of 11.5× in 2009 to a high of 1100.6× in 2011. The 5-year average is 34.4× and the 5-year median is 30.5×.

Question 7

What was Revvity's P/E ratio in 2025?

Accepted Answer

Revvity (RVTY) P/E ratio at the end of 2025 was 45.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Revvity's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$11B	$242M	45.3×	-0.5×	Dec 28, 2025
2024	$13.6B	$296M	45.8×	+27.0×	Dec 29, 2024
2023	$13.5B	$717M	18.8×	—	Dec 31, 2023
2022	—	$563M	—	—	Dec 31, 2022
2021	$25.4B	$923M	27.5×	+5.4×	Dec 31, 2021
2020	$16.1B	$728M	22.1×	-25.3×	Dec 31, 2020
2019	$10.8B	$228M	47.4×	+11.0×	Dec 31, 2019
2018	$8.69B	$239M	36.4×	-70.3×	Dec 31, 2018
2017	$8.13B	$76.2M	106.7×	+82.2×	Dec 31, 2017
2016	$5.73B	$234M	24.5×	-3.7×	Dec 31, 2016
2015	$6B	$212M	28.3×	-2.9×	Dec 31, 2015
2014	$4.92B	$158M	31.2×	+3.4×	Dec 31, 2014
2013	$4.64B	$167M	27.8×	-24.7×	Dec 31, 2013
2012	$3.65B	$69.6M	52.5×	-1048.1×	Dec 31, 2012
2011	$2.26B	$2.05M	1100.6×	+1080.6×	Dec 31, 2011
2010	$3.02B	$151M	20.0×	-6.6×	Dec 31, 2010
2009	$2.39B	$90.1M	26.6×	+14.4×	Dec 31, 2009
2008	$1.64B	$134M	12.2×	-11.3×	Dec 31, 2008
2007	$3.09B	$132M	23.4×	+0.3×	Dec 31, 2007
2006	$2.77B	$120M	23.2×	-17.4×	Dec 31, 2006
2005	$3.05B	$75.3M	40.5×	+10.5×	Dec 31, 2005
2004	$2.88B	$96M	30.0×	-9.9×	Dec 31, 2004
2003	$2.15B	$53.9M	39.9×	—	Dec 31, 2003
2002	$1.04B	-$15.1M	—	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Revvity (RVTY) 2003-2026

P/E Ratio daily chart for Revvity (RVTY)

Historical P/E Ratio for Revvity (RVTY) from 2002 to 2025

About P/E Ratio at Revvity (RVTY)

Revvity P/E Ratio by Year

Revvity P/E Ratio 2025: 45.3×

Revvity P/E Ratio 2024: 45.8×

Revvity P/E Ratio 2023: 18.8×

Revvity P/E Ratio 2021: 27.5×

Revvity P/E Ratio 2020: 22.1×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Revvity (RVTY) Key Financials